Author of

• 11645

  +

  P2.08 - Poster Session 2 - Radiotherapy (ID 198)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Radiation Oncology + Radiotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11655

    +

    P2.08-010 - Outcome of Epidermal Growth Factor Receptor mutated (EGFRm) non-small cell lung cancer (NSCLC) patients (p) with Brain metastases (BM) in a single institution: Value of the lung-GPA classification (ID 1309)

    09:30 - 09:30  |  Author(s): N. Codorniu
    • Abstract

    Background
    In February 2012 a specific GPA scale for assessing the prognosis of BM in NSCLC was published (JCO, 2012; 30(4): 419-426). Retrospective series have showed longer survival for patients with cerebral metastases and EGFR sensitizing mutations (m) compared with those without them.

    Methods
    Charts from EGFRm NSCLC p with BM were reviewed. We classified p with the lung-GPA prognosis scale at the time of diagnosis of BM and compared the expected GPA overall survival (GPA-OS) with the Observed OS (OS) for each group.

    Results
    24p were diagnosed from January 2007 to December 2012. 15 p were treated with whole-brain radiotherapy (WBRT), total dose 30Gy (2p GPA 0-1; 10p GPA 1.5-2; 3p GPA 2.5-3), 1 p with stereotactic radiosurgery (SRS), mean dose 18Gy (GPA 3.5-4), 1p with SRS and WBRT (GPA 2.5-3) and 2p with surgery (S) and WBRT (1p GPA 2.5-3; 1p GPA 3.5-4). 5p receive no treatment (3p GPA 0-1; 2p GPA 1.5-2). Outcomes were [Expected median (m) GPA-OS vs Observed m OS]:

    GPA	Expected m GPA-OS(months)	Observed m OS (months)	Number of p
    0-1	3.4	<1	5
    1.5-2	4.7	6	12
    2.5-3	8.8	34	5
    3.5-4	14.8	Not reached (100% OS at 40 months)	2

    Two p did not receive any EGFR tyrosine kinase inhibitor (TKI). 5p were receiving an EGFR TKI when they were diagnosed with BM and 12p were treated with EGFR TKI after the diagnosis of BM. Sixteen p have died. Further details of p characteristics and treatment received will be presented at the meeting.

    Conclusion
    Observed m OS of p with EGFR m-NSCLC and brain mets was much longer than expected by GPA-OS. The GPA subsets might predict prognosis in patients with mutated tumors as well.